Bhatt DL, Steg PG, Mehta SR, et al. - Through a phase 3 randomized, double-blinded, placebo-controlled trial, done across 1,315 sites in 42 countries, experts examined whether stable patients with coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI) would benefit from treatment with aspirin plus ticagrelor. Ticagrelor added to aspirin decreased cardiovascular death, myocardial infarction, and stroke—but with increased major bleeding in patients with diabetes, stable coronary artery disease, and prior PCI. Overall, ticagrelor offered a favorable net clinical advantage (more than in patients without a history of PCI). This influence explicates that long-term therapy with ticagrelor along with aspirin should be considered in patients with diabetes and a history of PCI who have endured antiplatelet therapy, have high ischemic risk, and low bleeding risk.